Spectral
Diagnostics
Decision Point Diagnostics™ |
CORPORATE DESCRIPTION:
Spectral Diagnostics Inc. remains dedicated to being the leader in the research, development and commercialization of decision point diagnostics. Our commitment to the development of new and novel rapid tests, such as the patented Cardiac Panel™, reagents and membranes, distinguishes the Company's approach to the diagnosis of cardiac and other serious conditions at the medical decision point. Spectral is a Canadian publicly traded company incorporated in 1991 with operations in Canada, the United States and Europe. Spectral's products are available worldwide.The American College of Cardiology and the European Society of Cardiology have changed the clinical and diagnostic definition of myocardial infarction. Current technology can detect areas of myocardial necrosis under 1 g in weight. Positive blood tests for cardiac troponin or CK-MB can accurately and reliably label these small infarcts as an MI. Spectral's proprietary technology utilizes a multiple cardiac marker approach. This allows a wide window for early and late chest pain presentations and provides the sensitivity and specificity to accurately rule in and rule out AMI within minutes.
Back
to top
Back to top
[ Home | Search | Index | Feedback ]
Last updated: 03/26/2003
Questions or corrections: Webmaster
© 2000 Medical Automation Systems, Inc. Legal Notice.